[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Sah SP, Jain BK, Lakhey M, Rani S: Mucinous carcinoma of rectosigmoid in a 15-year-old child: a case report. Indian J Pathol Microbiol; 2002 Jan;45(1):115-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of rectosigmoid in a 15-year-old child: a case report.
  • A 15-year-old girl with Duke's B mucinous carcinoma of the rectosigmoid was treated with surgical resection and adjuvant chemotherapy.
  • Colorectal carcinoma is extremely rare in children and adolescents.
  • Adenocarcinoma of colon is a virulent disease in children and has a poor prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colon, Sigmoid / pathology. Colorectal Neoplasms / pathology. Rectum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12593578.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Sim HL, Tan KY, Poon PL, Cheng A: Primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries. World J Gastroenterol; 2008 Apr 7;14(13):2118-20
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries.
  • However, primaries in the colon and rectum have also been reported.
  • Multiple scattered ulcers were also noted along the entire length of the colon.
  • Computed tomography scan of the abdomen and pelvis revealed circumferential tumour at the rectosigmoid junction with possible invasion into the left ischiorectal fossa.
  • The overall picture was that of a primary rectal signet ring cell carcinoma with peritoneal dissemination.
  • The patient was referred for palliative chemotherapy in view of the disseminated disease.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Colonoscopy / methods. Peritoneum / pathology. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1975 May-Jun;18(4):332-8 [165050.001]
  • [Cites] Cancer. 2004 May 1;100(9):1776-85 [15112256.001]
  • [Cites] ANZ J Surg. 2001 Dec;71(12):703-6 [11906382.001]
  • [Cites] APMIS. 2000 Jun;108(6):467-72 [11028811.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):183-8 [10981869.001]
  • [Cites] Cancer. 1978 Jun;41(6):2420-5 [207410.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1453-7 [6311394.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2723-6 [2996745.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] AMA Arch Surg. 1951 Jan;62(1):79-91 [14789350.001]
  • (PMID = 18395918.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2701538
  •  go-up   go-down


3. Zamir N, Ahmed S, Akhtar J: Mucinous adenocarcinoma of colon. APSP J Case Rep; 2010 Jul;1(2):20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of colon.
  • Bleeding per rectum is a common complaint in pediatric age group and mostly relates to benign conditions.
  • Underlying colorectal carcinoma is a rare cause and carries a poor prognosis.
  • We report two cases of mucinous adenocarcinoma of colon, one in a 9 years old male and other in a female of 12 years.
  • He had mucinous adenocarcinoma (T3N0MX) of rectosigmoid region and underwent local complete resection of the tumor with colostomy.
  • He also received postoperative chemotherapy and later underwent colostomy reversal.
  • The girl presented with signs of intestinal obstruction and at colonoscopy a stricture found in descending colon.
  • She is on chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Oct-Dec;39(4):218-9 [7527858.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] Indian Pediatr. 2001 Aug;38(8):933-4 [11521016.001]
  • [Cites] Paediatr Drugs. 2008;10(3):177-92 [18454570.001]
  • [Cites] Indian J Cancer. 2008 Jul-Sep;45(3):119-22 [19018116.001]
  • [Cites] Afr J Paediatr Surg. 2009 Jan-Jun;6(1):65-7 [19661674.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Ayub Med Coll Abbottabad. 2007 Jul-Sep;19(3):56-63 [18444593.001]
  • (PMID = 22953263.001).
  • [ISSN] 2218-8185
  • [Journal-full-title] APSP journal of case reports
  • [ISO-abbreviation] APSP J Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Other-IDs] NLM/ PMC3417995
  • [Keywords] NOTNLM ; Bleeding per rectum / Child / Mucinous adenocarcinoma / Colorectum
  •  go-up   go-down


Advertisement
4. Yumuk PF, Abacioglu U, Caglar H, Gumus M, Sengoz M, Turhal NS: Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital. J Chemother; 2003 Dec;15(6):603-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital.
  • Adjuvant chemoradiotherapy is the standard treatment in resected stage II/III rectosigmoid carcinoma.
  • Radiotherapy was started at 7th week and 45-50.4 Gy was given to pelvic region.
  • Protracted short-term infusion of 5-fluorouracil during pelvic irradiation is a safe treatment modality.
  • Further studies are needed to improve the local control of high-risk rectal and sigmoid carcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Colectomy / methods. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Hospitals, University. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. Turkey

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14998088.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Pahlavan PS, Kanthan R: The epidemiology and clinical findings of colorectal cancer in Iran. J Gastrointestin Liver Dis; 2006 Mar;15(1):15-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology and clinical findings of colorectal cancer in Iran.
  • BACKGROUND: This study was performed to evaluate the prevalence, clinical features and management of patients with colorectal cancer (CRC) in Iran.
  • The tumors were categorized according to their distribution as appendix (n=4), cecum ( n=7), right colon (n=1), hepatic flexure (n=2), transverse colon (n=19), splenic flexure (n=3), left colon (n=6), sigmoid ( n=16), rectum (n=117), rectosigmoid and rectal lesions (n=16), and colorectal lesions without known locations (n=9).
  • Non-mucinous adenocarcinoma (AC) was the most common histological type (n=181, 90%), followed by mucinous AC (n=15), squamous cell carcinoma (n=1), carcinoid (n=1), melanoma (n=1) and signet ring carcinoma (n=1).
  • Younger patients had a greater preponderance of mucinous AC (p=0.008) and generally underwent more extensive chemotherapy as seen with more usage of 5-Fluorouracil (p=0.05).
  • We found no significant difference between age, gender and type of cancer with subsite distribution.
  • Distal CRC was more prevalent.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680227.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


6. Lindel K, Willett CG, Shellito PC, Ott MJ, Clark J, Grossbard M, Ryan D, Ancukiewicz M: Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. Radiother Oncol; 2001 Jan;58(1):83-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
  • BACKGROUND AND PURPOSE: To update and summarize the experience at the Massachusetts General Hospital of a treatment program of high-dose preoperative irradiation, surgical re-resection, and intraoperative radiation therapy (IORT) as a salvage treatment for patients with recurrent rectal or rectosigmoid carcinoma.
  • PATIENTS AND METHODS: From June 1978 to February 1997, the records of 69 patients with locally recurrent rectal carcinomas or rectosigmoid carcinomas without metastases referred for consideration of IORT were reviewed.
  • Chemotherapy had no significant influence on overall or disease-free survival.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Rectal Neoplasms / radiotherapy. Sigmoid Neoplasms / radiotherapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Radiation. Fluorouracil / therapeutic use. Humans. Intraoperative Care. Neoplasm Staging. Preoperative Care. Salvage Therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11165686.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Park SS, Kim BK, Kim CJ, Kim WS, Kim IO, Park KW, Shin HY, Ahn HS: Colorectal adenocarcinoma as a second malignant neoplasm following rhabdomyosarcoma of the urinary bladder: a case report. J Korean Med Sci; 2000 Aug;15(4):475-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following improvements in therapy for childhood malignancies, the striking increase in survival rate over the past 30 years has led to the increase risk of developing second malignant neoplasms (SMNs).
  • We report a case of colorectal carcinoma as a SMN, following treatment for rhabdomyosarcoma.
  • The patient was diagnosed with rhabdomyosarcoma of the urinary bladder at his age of three years, and developed adenocarcinoma in the colon 13 years later.
  • Histologic examination of the surgical specimen revealed adenocarcinoma involving the rectosigmoid area with radiation colitis in its background.
  • This case emphasizes the need for dose observation in survivors of early childhood malignancies treated with radiation and multiagent chemotherapy.
  • [MeSH-major] Adenocarcinoma / etiology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects. Rhabdomyosarcoma. Urinary Bladder Neoplasms
  • [MeSH-minor] Adolescent. Colitis / etiology. Colitis / pathology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Genes, p53. Humans. Male. Neoplasm Proteins / analysis. Radiation Injuries / etiology. Radiation Injuries / pathology. Sigmoid Neoplasms / etiology. Sigmoid Neoplasms / genetics. Sigmoid Neoplasms / pathology. Time Factors. Tumor Suppressor Protein p53 / analysis. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983702.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] KOREA (SOUTH)
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC3054655
  •  go-up   go-down


8. Bhutani MS, Nadella P: Utility of an upper echoendoscope for endoscopic ultrasonography of malignant and benign conditions of the sigmoid/left colon and the rectum. Am J Gastroenterol; 2001 Dec;96(12):3318-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of an upper echoendoscope for endoscopic ultrasonography of malignant and benign conditions of the sigmoid/left colon and the rectum.
  • OBJECTIVE: The majority of data on colonic endoscopic ultrasound (EUS) are limited to malignant lesions in the rectum and diseases of the anal sphincter.
  • The forward-oblique-viewing upper echoendoscope has been mostly applied for staging rectal cancer.
  • The purpose of our study was to evaluate the utility of a forward-oblique-viewing upper echoendoscope for EUS of malignant and benign lesions of the sigmoid/left colon and the rectum.
  • METHODS: Thirty-two EUS exams were performed for a variety of indications in the rectum and the sigmoid/left colon.
  • RESULTS: Twenty-six exams were done for staging of rectosigmoid carcinoma, follow-up after chemotherapy and/or radiation, or to look for recurrence after resection of colorectal cancer.
  • One patient subsequent to EUS imaging also underwent a linear EUS-guided fine-needle aspiration of a submucosal mass in the rectum with the fine-needle aspirate consistent with a myogenic tumor.
  • CONCLUSIONS: The forward-oblique-viewing upper echoendoscope is a versatile instrument that can be applied for EUS imaging of malignant and benign indications not only in the rectum but also in the sigmoid/left colon.
  • [MeSH-major] Colon / ultrasonography. Colonic Diseases / ultrasonography. Endoscopes / standards. Endosonography / instrumentation. Rectal Diseases / ultrasonography. Rectum / ultrasonography
  • [MeSH-minor] Colon, Sigmoid / ultrasonography. Colonic Neoplasms / ultrasonography. Humans. Neoplasm Staging / methods. Rectal Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11774943.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Luccichenti G, Cademartiri F, Sianesi M, Roncoroni L, Pavone P, Krestin GP: Radiologic assessment of rectosigmoid cancer before and after neoadjuvant radiation therapy: comparison between quantitation techniques. AJR Am J Roentgenol; 2005 Feb;184(2):526-30
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiologic assessment of rectosigmoid cancer before and after neoadjuvant radiation therapy: comparison between quantitation techniques.
  • OBJECTIVE: Volumetric analysis was compared with conventional unidimensional measurements for follow-up of rectosigmoid cancer before and after radiation therapy.
  • SUBJECTS AND METHODS: Fifteen patients with rectosigmoid cancer underwent helical CT before and after neoadjuvant radiation therapy.
  • The helical CT examination was performed after colon distention with air and IV administration of an antiperistaltic drug.
  • RESULTS: The mean of the differences between the volumetric analysis of the scans obtained before and after radiation therapy was 8.3 +/- 10.3 (SD) mL (-22.7%) (p <0.05).
  • The mean of the differences between the maximal wall thickness of the pre- and post-radiation therapy scans was 3.4 +/- 2.6 mm (-19.1%) (p <0.05).
  • A significant difference was observed between the variation of the maximal wall thickness and the variation of volumetric analysis in pre- and post-radiation therapy scans (p <0.05).
  • CONCLUSION: Volumetric analysis of rectosigmoid cancer is feasible.
  • [MeSH-major] Rectal Neoplasms / radiography. Rectal Neoplasms / radiotherapy. Sigmoid Neoplasms / radiography. Sigmoid Neoplasms / radiotherapy. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Female. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Male. Middle Aged. Neoadjuvant Therapy. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671374.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Copur S, Ledakis P, Novinski D, Mleczko KL, Frankforter S, Bolton M, Fruehling RM, VanWie E, Norvell M, Muhvic J: Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. Clin Colorectal Cancer; 2001 May;1(1):55-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.
  • The most commonly reported anatomic locations are the rectum and the proximal colon.
  • Because of their extremely rare occurrence, it is difficult to study their natural course, clinical behavior, and response to therapy.
  • This report presents the case of a pure squamous cell colorectal cancer and provides a brief review of the literature, which includes 60 previously published cases.
  • The case of a patient with T3N2M0 primary squamous cell carcinoma of the rectosigmoid colon, which was initially treated with abdominoperineal resection followed by adjuvant chemotherapy and radiation, is presented.
  • During the follow-up, an elevated squamous cell carcinoma antigen (SCC Ag) level led to restaging computed tomography scans, which confirmed recurrent metastatic disease in the liver.
  • Response to chemotherapy with a decrease in tumor size correlated with a decrease in the serum SCC Ag level.
  • Although SCC Ag has been used as a tumor marker for squamous cell cancers of the lung, head and neck, uterine cervix, and esophagus, this is the first reported case of a squamous cell colon carcinoma presenting with an elevated SCC Ag at the time of recurrence.
  • In addition, this patient showed an objective partial response to combination chemotherapy, with a decrease in the serum level of this tumor marker.
  • [MeSH-major] Antigens, Neoplasm / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / drug therapy. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Serpins
  • [MeSH-minor] Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445380.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Serpins; 0 / squamous cell carcinoma-related antigen; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Scarabelli C, Gallo A, Franceschi S, Campagnutta E, De G, Giorda G, Visentin MC, Carbone A: Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer; 2000 Jan 15;88(2):389-97
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma.
  • BACKGROUND: The impact of radical bowel resection with multiple organ resection on the survival if patients with advanced ovarian carcinoma has not been well defined.
  • The authors investigated whether primary cytoreductive surgery including rectosigmoid colon resection would affect the recurrence free interval and survival of these patients.
  • METHODS: Between April 1990 and April 1997, 66 previously untreated Stage IIIC-IV ovarian carcinoma patients with macroscopic involvement of the rectosigmoid colon were enrolled.
  • All patients underwent cytoreductive surgery with rectosigmoid colon resection to remove residual tumor less than 2 cm in greatest dimension and received 6 cycles of cisplatin-based postoperative chemotherapy.
  • Overall, 48 patients (72.7%) developed disease recurrence: 43 (65.1%) in the abdomen, 19 (29.8%) in the liver, and 3 (4.5%) in the pelvis.
  • CONCLUSIONS: The current findings suggest that cytoreductive surgery with rectosigmoid colon resection should be considered for ovarian carcinoma patients with bulky pelvic disease to help ensure that they are left with no residual disease after debulking surgery.
  • [MeSH-major] Carcinoma / surgery. Colon, Sigmoid / surgery. Neoplasm Recurrence, Local. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10640973.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


12. Polglase AL, McMurrick PJ, Tremayne AB, Bhathal PS: Local recurrence after curative anterior resection with principally blunt dissection for carcinoma of the rectum and rectosigmoid. Dis Colon Rectum; 2001 Jul;44(7):947-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence after curative anterior resection with principally blunt dissection for carcinoma of the rectum and rectosigmoid.
  • PURPOSE: The aim of this study was to determine the incidence of local pelvic recurrence of carcinoma of the rectum and rectosigmoid (tumors where the lower edge is 18 cm or less from the anal verge) in a consecutive series of patients operated on by a single surgeon.
  • All patients underwent curative anterior resection and a formal anatomic dissection of the rectum where mobilization was achieved through a principally careful blunt manual technique along fascial planes, preserving an oncologic package.
  • METHOD: During the period April 1986 to December 1997, 157 consecutive anterior resections for carcinoma of the rectum and rectosigmoid were performed by one surgeon (ALP).
  • Local recurrences occurred between 16 and 38 months from the time of resection, and the cumulative risk of developing local recurrence at five years was 5.2 percent.
  • Local recurrence developed in 3 of 28 (10.7 percent) patients having ultralow anterior resection, 1 of 57 (1.8 percent) patients having low anterior resection (between 6 and 10 cm from the anal verge), and no patients having high anterior resection (above 10 cm from the anal verge).
  • The overall five-year cancer-specific survival rate of the entire group of 131 patients was 81.8 percent, and the overall probability of being disease free at five years including both local and distal recurrence was 72.9 percent.
  • Three local recurrences occurred in the 101 patients (77 percent) who did not receive any form of adjuvant therapy.
  • No recurrence occurred in the 12 patients (9.2 percent) who had adjuvant chemotherapy alone.
  • CONCLUSION: Curative anterior resection for carcinoma of the rectum and rectosigmoid with principally blunt dissection of the rectum in this study is associated with a 3.1 percent incidence and a 5.2 percent probability at five years of developing local recurrence.
  • [MeSH-major] Carcinoma / surgery. Digestive System Surgical Procedures / methods. Neoplasm Recurrence, Local. Rectal Neoplasms / surgery. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496074.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Matter MJ, Gygi C, Gillet M, Gebhard S, Bouzourene H: Malacoplakia simulating organ invasion in a rectosigmoid adenocarcinoma: report of a case. Dis Colon Rectum; 2001 Sep;44(9):1371-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malacoplakia simulating organ invasion in a rectosigmoid adenocarcinoma: report of a case.
  • He presented with a rectosigmoid tumor that seemed to infiltrate the urinary bladder and the sacrum on the preoperative CT scan and echography and at laparotomy.
  • The pathologic analysis showed a pT3pN0 adenocarcinoma with an extensive malacoplakia infiltrating the bladder and the pericolic and perirectal tissues.
  • Our observation confirms the association of malacoplakia, colorectal carcinoma, and steroid treatment.
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Diagnosis, Differential. False Positive Reactions. Humans. Inflammation. Lung Diseases / drug therapy. Male. Neoplasm Invasiveness. Neoplasm Staging. Steroids / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584219.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


14. Ghosh K, Geller MA, Twiggs LB: Erosion of an intraperitoneal chemotherapy catheter resulting in an enterovaginal fistula. Gynecol Oncol; 2000 May;77(2):327-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erosion of an intraperitoneal chemotherapy catheter resulting in an enterovaginal fistula.
  • BACKGROUND: With the pharmacokinetic advantages of intraperitoneal chemotherapy delivery and the increased popularity of immunotherapy and gene therapy, intraperitoneal catheters have moved to the forefront as a delivery system in cancer treatment.
  • This delivery system, however, carries with it an intrinsic morbidity warranting attention in the often prolonged chemotherapy regimens demanded by cancer patients.
  • Our patient, diagnosed with persistent ovarian carcinoma, had a peritoneal Tenckoff catheter placed for chemotherapy.
  • Many months after termination of the chemotherapy and 15 months after placement, she presented with bowel contents per vagina.
  • A CT scan revealed an abdominopelvic abscess encompassing the detached catheter which embedded in the rectosigmoid colon, allowing direct communication to the upper vagina.
  • [MeSH-minor] Catheters, Indwelling / adverse effects. Equipment Failure. Female. Humans. Infusions, Parenteral. Middle Aged. Morbidity. Ovarian Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10785489.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Samareh Pahlavan P: The epidemiology, clinical findings and prognosis of colorectal cancer in Iran. J Clin Oncol; 2004 Jul 15;22(14_suppl):9630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology, clinical findings and prognosis of colorectal cancer in Iran.
  • : 9630 Background: This study was performed to evaluate the clinical features and outcome of patients with Colorectal cancer (CRC) in Iran.
  • METHODS: All cases of CRC presented to a main countryside referral University hospital (SGH) for cancers in Teheran, Iran between June 20,2000 and January 3,2003 were retrospectively reviewed to determine age, gender, subsite distribution, early symptoms, ethnicity, type of the CRC and the chemotherapy management.
  • RESULTS: A total of 200 patients were included .114 patients (57.0%) were male and 86 were female (43.0%) .Age ranged from 13-90 years with a mean of 55.15+/- 14.5 years.16.5% of patients were below 40 years of age.The tumors were classified as : appendix (n=4), cecum ( n=7), Right Cancers (RC), from the cecum to hepatic flexure (n=1), hepatic flexure ( n=2), Transverse Colon (n=19), Splenic Flexure (n=3), Left Colon (LC) from the Splenic Flexure down to Sigmoid (n=6), Sigmoid ( n=16), Rectum ( n=117), Rectosigmoid & Rectal lesions (n=16), and Colorectal lesions without known locations (n=9).
  • Non-Mucinous Adenocarcinoma was the most common (n=181, 90%), followed by Mucinous AC (n=15), SCC (n=1), Carcinoid (n=1), Melanoma (n=1), Signet ring carcinoma (n=1).
  • 37% of patients had anemia at the time of diagnosis.
  • 130 of patients underwent chemotherapy and the combination of 5-FU and Leucovorin was predominanat. (n=104, 52%) Younger patients significantly had more Mucinous AC (p=.008) and took more 5-FU.(p=0.05) Conclusions: We have no reports from the Epidemiology of CRC in Iran since 1977. the data suggested a younger age distribution for CRC .
  • we found no significant difference between age, gender and type of cancer with subsite distribution .
  • Distal (left-sided) CRC was more prevalent.
  • 30.5% of patients were diagnosed by screening studies which highly suggests the procedure.
  • Anemia was less common in our population. younger patients received medical attention and 5-FU medication earlier and more.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016212.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Clemente G, Chiarla C, Giovannini I, De Rose AM, Astone A, Barone C, Nuzzo G: Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer. Curr Med Res Opin; 2010 Mar;26(3):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer.
  • OBJECTIVES: Acute abdominal symptoms with CT scan evidence of intramural gas in bowel walls (pneumatosis cystoides intestinalis, PCI) and of gas in the portal venous blood (PBG) in patients undergoing chemotherapy may represent a worrisome picture, suggestive of bowel necrosis.
  • We describe a patient with acute abdominal symptoms and evidence of PCI with PBG under cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy for metastatic adenocarcinoma of the rectosigmoid junction.
  • METHODS: After admission for mucositis with diarrhea and profound dehydration, and subsequent emergency laparotomy for derotation of an intestinal volvulus, on the tenth postoperative day the patient developed fever and abdominal pain, with CT scan evidence of PCI with PBG.
  • The exam of the abdomen did not suggest major problems requiring emergency surgery, and antibiotic treatment with close monitoring were performed, followed by rapid improvement.
  • Subsequently recovery was normal and at present, after 15 months, the patient is well and continuing chemotherapy.
  • CONCLUSIONS: This is probably the first report of PCI with PBG related to intestinal toxicity during cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy in a patient with advanced rectal carcinoma, followed by delayed small bowel perforation.
  • It provides an example of the challenges involved in the management of this type of patient.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Gases. Pneumatosis Cystoides Intestinalis. Portal Vein / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Cetuximab. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology. Tegafur / administration & dosage. Tegafur / adverse effects

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078321.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Gases; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 1548R74NSZ / Tegafur; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin
  •  go-up   go-down


17. Suzuki R, Nakata K, Okamura S, Kanemura T, Yanai A, Kobayashi M, Yoshioka Y, Uji K, Yoshida A, Takeno A, Nakahira S, Miki H, Sugimoto K, Tamura S: [Case report--a long-term surviving patient who received lymph node dissection of skip metastasis from rectosigmoid cancer to bilateral lateral lymph nodes]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2598-600
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report--a long-term surviving patient who received lymph node dissection of skip metastasis from rectosigmoid cancer to bilateral lateral lymph nodes].
  • Skip metastasis in colorectal cancer consists of about 10% of lymph node metastases.
  • A forty-two years old female received anterior resection for advanced rectosigmoid cancer.
  • Because pathological stage of the patient was stage IIIa (T3N1M0), standard adjuvant chemotherapy was provided.
  • [MeSH-minor] Adult. Carcinoembryonic Antigen / analysis. Chemotherapy, Adjuvant. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224651.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


18. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol; 2006 Jan;100(1):27-32
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
  • OBJECTIVES: To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully complete six cycles of IP chemotherapy.
  • METHODS: In a phase III trial, women with optimal stage III ovarian or peritoneal carcinoma were randomly allocated to receive IP therapy (paclitaxel 135 mg/m(2) intravenously (IV) over 24 h, cisplatin 100 mg/m(2) IP day 2, paclitaxel 60 mg/m(2) IP day 8) every 21 days for six cycles.
  • Patients unable to receive IP therapy were treated with the alternate (IV) regimen.
  • Variables compared included surgical procedures prior to enrollment, timing of IP catheter insertion, and primary and contributing reasons for discontinuing IP therapy.
  • RESULTS: Among 205 eligible patients randomly allocated to the IP arm, 119 (58%) did not complete six cycles of IP therapy.
  • Forty (34%) patients discontinued IP therapy primarily due to catheter complications and 34 (29%) discontinued for unrelated reasons.
  • IP therapy was not initiated in 16% of patients who did versus 5% of those who did not have a left colon or rectosigmoid colon resection (P = 0.015).
  • There was no association between timing of catheter insertion and failure to complete IP therapy.
  • CONCLUSIONS: In this multi-institutional setting, it was difficult to deliver six cycles of IP therapy without complications.
  • There appears to be an association between rectosigmoid colon resection and the inability to initiate IP therapy.
  • Catheter choice, timing of insertion, and how surgical treatment of ovarian cancer influences the successful completion of intraperitoneal chemotherapy require further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Catheters, Indwelling / adverse effects. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2006 Jul;102(1):129; author reply 130 [16600354.001]
  • [CommentIn] Gynecol Oncol. 2006 Jan;100(1):3-4 [16368439.001]
  • (PMID = 16368440.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Lincourt AE, Sing RF, Kercher KW, Stewart A, Demeter BL, Hope WW, Lang NP, Greene, Heniford BT: Association of demographic and treatment variables in long-term colon cancer survival. Surg Innov; 2008 Mar;15(1):17-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of demographic and treatment variables in long-term colon cancer survival.
  • The purpose of this study is to examine demographic and treatment variables because they relate to 5-year survival in colon cancer.
  • The study design is analysis of 174 471 patients with colon and rectosigmoid cancer as reported to the American College of Surgeons National Cancer Data Base.
  • Factors associated with a reduced risk of mortality included female gender (hazard ratio = 0.89; 95% confidence interval, 0.87-0.90), education status (hazard ratio = 0.87; 95% confidence interval, 0.85-0.89), increased number of lymph nodes resected (compared with <8, 8-12: hazard ratio = 0.90; 95% confidence interval, 0.89-0.92; >12: hazard ratio = 0.79; 95% confidence interval, 0.77-0.80), and addition of chemotherapy (hazard ratio = 0.69; 95% CI, 0.68-0.71).
  • Survival in colon cancer is significantly impacted by patient's age, race, gender, and education status but not by income or area of residence.
  • [MeSH-major] Colonic Neoplasms / therapy. Demography. Rectal Neoplasms / therapy. Sigmoid Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Sex Factors. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18388001.001).
  • [ISSN] 1553-3506
  • [Journal-full-title] Surgical innovation
  • [ISO-abbreviation] Surg Innov
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Abraham NS, Gossey JT, Davila JA, Al-Oudat S, Kramer JK: Receipt of recommended therapy by patients with advanced colorectal cancer. Am J Gastroenterol; 2006 Jun;101(6):1320-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receipt of recommended therapy by patients with advanced colorectal cancer.
  • OBJECTIVES: To evaluate utilization of surgery, chemotherapy, and radiation therapy among patients with stage II or III colon cancer and stage II/III rectal or rectosigmoid cancer, as recommended by current national guidelines.
  • DeBakey Veterans Affairs Medical Center (Houston, TX) used 1999-2003 administrative data to identify patients with a diagnostic code for colorectal cancer.
  • Medical charts were then abstracted to identify an incident cohort with stage II or III cancer.
  • Outcome of interest was receipt of recommended therapy defined as surgery only (stage II colon) or surgery with adjuvant chemo- or radiotherapy (stage III colon or stage II/III rectal/rectosigmoid cancer).
  • Potential determinants of receipt of recommended therapy were analyzed using logistic regression.
  • A gastroenterologist diagnosed 72.5% tumors including 62 stage II colon, 62 stage III colon, and 73 stage II/III rectal cancers.
  • Referral to oncology occurred in 76% of stage II colon, 92% of stage III colon, and 99% of rectal cancers.
  • 87% of stage II and 71% of stage III colon cancer patients received recommended therapy, compared to only 42.5% of rectal cancer patients.
  • Predictors of receipt of recommended therapy among rectal cancers included being married (OR, 5.3; 95% CI: 1.6-17.1), presentation at tumor board (OR, 3.6; 95% CI: 1.2-11.2), or age<65 yr (OR, 3.5; 95% CI: 1.3-9.3).
  • When patient's comorbidity and physician's decision-making process were considered in the assessment of the outcome, only presentation at tumor board remained predictive of receipt of recommended therapy.
  • CONCLUSIONS: Most colon cancer patients at a major VA medical center receive recommended therapy.
  • Among rectal cancer patients, those presented at tumor board are most likely to receive recommended therapy.
  • [MeSH-major] Colorectal Neoplasms / therapy. Patient Acceptance of Health Care

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16771956.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


21. Aoyagi H, Kaneko J, Ono H, Isogai J, Yoshida M, Someno Y, Katsuta E, Saguchi M, Takahata T, Hasegawa K, Hamada S, Higuchi T, Sugihara K, Maejima S: [A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2433-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].
  • Contrast enhanced abdominal CT showed a rectosigmoid tumor invading the left pelvic wall and multiple metastatic hepatic tumors.
  • Colonoscopy showed a type-2 cancer in the rectosigmoid region.
  • The patient underwent sigmoid colostomy 3 days after admission.
  • Postoperative upper gastrointestinal endoscopy showed a type 3 cancer in the fornix.
  • From the above findings, the patient was diagnosed with unresectable gastric and rectosigmoid cancers with multiple hepatic metastases, and systemic chemotherapy was initiated.
  • The first line treatment was two courses of S-1, but it was discontinued due to PD.
  • FOLFIRI was begun as the second line treatment.
  • Twelve courses of FOLFIRI chemotherapy were performed in total.
  • However, the gastric lesion had been controlled well after the second line treatment.
  • The findings of the present study suggested that FOLFIRI could be an effective treatment for unresectable multiple advanced cancers of the stomach and colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / therapy. Sigmoid Neoplasms / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224597.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


22. Liang JT, Lai HS, Lee PH: Laparoscopic medial-to-lateral approach for the curative resection of right-sided colon cancer. Ann Surg Oncol; 2007 Jun;14(6):1878-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic medial-to-lateral approach for the curative resection of right-sided colon cancer.
  • INTRODUCTION: Our previous randomized clinical trial comparing the laparoscopic medial-to-lateral dissection with the more classic lateral-to-medial approach for resection of rectosigmoid cancer showed that the medial approach reduces the operative time and the postoperative proinflammatory response.
  • Besides the oncologic advantages of an early vessel division and a "no-touch" dissection, we feel that the longer the lateral abdominal wall attachments of the colon are preserved, the better the exposure and the easier the dissection.
  • Encouraged by the above-mentioned positive findings, we therefore further conduct this phase II clinical trial to examine the feasibility and surgical outcomes regarding the utilization of this medial-to-lateral laparoscopic dissection approach for the curative resection of right-sided colon cancer.
  • METHODS: A total of 104 patients (from December 2000 to January, 2005) with advanced right-sided colon cancer (TNM stage II: n = 56; stage III: n = 48) requiring a curative right hemicolectomy were subjected to the laparoscopic medial-to-lateral approach that included initial exploration and ligation of ileocolic, right colic, and middle colic vessels in no-touch isolation fashion, subsequent medial-to-lateral extension of retroperitoneal dissection along Gerota fascia, opening of lesser sac by transection of gastrocolic ligament, and the final mobilization of hepatic flexure and lateral attachments of ascending colon (Fig. 1).
  • Postoperatively, adjuvant chemotherapy with Mayo Clinic Regimen was given in patients with stage III diseases.
  • RESULTS: The laparoscopic medial-to-lateral approach for a curative right hemicolectomy can be preformed with acceptable operation time (192.6 +/- 32.8 min, mean +/- standard deviation) and little blood loss (48.4 +/- 14.4 ml) through a small wound (6.0 +/- 0.8 cm).
  • During the follow-up periods (median: 30 months, range 6-55 months), recurrence of tumor developed in 6 (10.7%) of stage II and 10 (20.8%) of stage III patients, with liver metastasis in six patients, lung metastasis in 4, liver and lung metastasis in 1, intraperitoneal recurrence in 2, bone metastasis in 1, brain metastasis in 1, and port-site recurrence in 1.
  • [MeSH-major] Colectomy / methods. Colon, Ascending / surgery. Colonic Neoplasms / surgery. Laparoscopy / methods
  • [MeSH-minor] Blood Loss, Surgical. Chemotherapy, Adjuvant. Dissection / methods. Feasibility Studies. Follow-Up Studies. Hospitalization. Humans. Ileus / etiology. Ligaments / surgery. Ligation. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Pain, Postoperative / etiology. Postoperative Complications. Prospective Studies. Recovery of Function / physiology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377832.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Law WL, Chu KW: Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol; 2006 Jun 1;93(7):523-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection of stage IV rectal cancer with mesorectal excision.
  • BACKGROUND: There is no consensus as to the management of the primary rectal cancer in the presence of distant metastasis and data on the outcomes of radical resection in stage IV rectal cancer are limited.
  • This study aims to evaluate the results of resection of rectal cancer in the patients with stage IV disease and to analyze the factors that might affect the survival of these patients.
  • METHODS: Of the 744 patients with radical resection of primary rectal and rectosigmoid cancer during the study period from August 1993 to July 2002, 70 had stage IV disease on the initial presentation.
  • The median cancer-specific survival of the patients who survived the surgery was 15.2 months.
  • Multivariate analysis showed that the presence of gross residual local disease, lymph node metastasis, liver involvement of over 50%, the absence of surgical management of liver metastasis and those without chemotherapy were independent factors associated with poor survival.
  • CONCLUSIONS: Postoperative mortality and morbidity were acceptable in patients with stage IV rectal cancer.
  • Surgical management of the metastasis and the administration of chemotherapy are associated with better survival.
  • However, the optional treatment regimes are yet to be defined.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery. Rectum / surgery. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Peritoneal Neoplasms / secondary. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16705728.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Dauplat J, Le Bouëdec G, Pomel C, Scherer C: Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol; 2000 Jul-Aug;19(1):42-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery for advanced stages of ovarian cancer.
  • During the past two decades, maximum cytoreductive surgery (also called debulking surgery) has been the recommended surgical approach for advanced stages of ovarian carcinoma.
  • A well-trained surgeon in the field of gynecologic oncology can achieve an optimal tumor reduction in up to 75% of patients with advanced stage ovarian cancer.
  • During the procedure, bowel resection, especially rectosigmoid, must be undertaken in 30% to 40% of cases, and para-aortic and pelvic lymphadenectomy should be performed after adequate tumor reduction in the abdominal cavity.
  • The experienced surgeon can perform these surgeries with an acceptable morbidity, allowing chemotherapy to be undertaken within the month following surgery.
  • However, very advanced cancer with massive peritoneal carcinomatosis and/or Stage IV disease requires a very aggressive surgical procedure but yields a poor prognosis and a higher risk of unacceptable complications.
  • For these worst cases, the concept of cytoreductive surgery is moving toward the alternative strategy of chemosurgical cytoreduction, in which interval cytoreductive surgery is undertaken after three cycles of front-line chemotherapy.
  • The goal of this experimental strategy is to achieve a complete tumor response after front-line chemosurgical therapy, and a better quality of life.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10883023.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 55
  •  go-up   go-down


25. Peiretti M, Zakashansky K, Melis GB, Mais V: Unusual case of adenocarcinoma arising in endometriosis mimicking colorectal cancer in a young woman with a Müllerian anomaly. Fertil Steril; 2008 Jul;90(1):199.e13-5
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case of adenocarcinoma arising in endometriosis mimicking colorectal cancer in a young woman with a Müllerian anomaly.
  • OBJECTIVE: To report a case of endometrioid adenocarcinoma that arose in endometriosis mimicking colorectal cancer in a young woman with a Müllerian anomaly.
  • A solid rectosigmoid mass adherent to the left pelvic sidewall was found in this patient.
  • INTERVENTION(S): The patient was subjected to an exploratory laparotomy followed by adjuvant chemotherapy.
  • RESULT(S): Intraoperative and histologic examinations revealed endometriosis-associated colorectal cancer.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Colorectal Neoplasms / diagnosis. Endometriosis / complications. Mullerian Ducts / abnormalities
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Hysterectomy. Ileostomy. Laparoscopy. Lymph Node Excision. Ovariectomy. Pelvic Pain / etiology. Treatment Outcome


26. Cheng JC, Peng LC, Chen YH, Huang DY, Wu JK, Jian JJ: Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy. Int J Radiat Oncol Biol Phys; 2003 Nov 15;57(4):1010-8
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy.
  • PURPOSE: To investigate the correlation of the radiation dose to the upper rectum, proximal to the International Commission of Radiation Units and Measurements (ICRU) rectal point, with late rectal complications in patients treated with external beam radiotherapy (EBRT) and high-dose-rate (HDR) intracavitary brachytherapy (ICRT) for carcinoma of the uterine cervix.
  • METHODS AND MATERIALS: Between June 1997 and February 2001, 75 patients with cervical carcinoma completed definitive or preoperative RT and were retrospectively reviewed.
  • Of the 62 patients, 36 (58%) also received concurrent chemotherapy, mainly with cisplatin during EBRT.
  • EBRT consisted of a mean of 50.1 +/- 1.3 Gy of 18-MV photons to the pelvis.
  • Central shielding was used after 40-45 Gy of pelvic RT.
  • HDR ICRT followed EBRT, with a median dose of 5 Gy/fraction given twice weekly for a median of four fractions.
  • The mean dose to point A from HDR ICRT was 23.9 +/- 3.0 Gy.
  • In addition to the placement of a rectal tube with a lead wire during ICRT, 30-40 mL of contrast medium was instilled into the rectum to demonstrate the anterior rectal wall up to the rectosigmoid junction.
  • Late rectal complications were recorded according to the Radiation Therapy Oncology Group grading system.
  • The maximal rectal dose taken along the rectum from the anal verge to the rectosigmoid junction and the ICRU rectal dose were calculated.
  • RESULTS: Fourteen patients (23%) developed Grade 2 or greater rectal complications.
  • Patient-related factors, definitive or preoperative RT, and the use of concurrent chemotherapy were not associated with the occurrence of rectal complications.
  • The maximal rectal dose during ICRT was at the proximal rectum rather than at the ICRU rectal point in 55 (89%) of 62 patients.
  • Patients with Grade 2 or greater rectal complications had received a significantly greater total maximal proximal rectal dose from ICRT (25.6 Gy vs. 19.2 Gy, p = 0.019) and had a greater maximal proximal rectal dose/point A dose ratio (1.025 vs. 0.813, p = 0.024).
  • In contrast, patients with and without rectal complications had a similar dose at point A (25.0 Gy vs.23.6 Gy, p = 0.107).
  • The differences in the ICRU rectal dose (17.8 Gy vs.15.4 Gy, p = 0.065) and the ICRU rectal dose/point A dose ratio (0.71 vs. 0.66, p = 0.210) did not reach statistical significance.
  • Patients with >62 Gy of a direct dose sum from EBRT and ICRT to the proximal rectum (12 of 29 vs. 2 of 33, p = 0.001) and >110 Gy of a total maximal proximal rectal biologic effective dose (13 of 40 vs. 1 of 22, p = 0.012) presented with a significantly increased frequency of Grade 2 or greater rectal complications.
  • Moreover, 11 of the 14 patients with rectal complications had colonoscopic findings of radiation colitis at the proximal rectum, the area with the maximal rectal dose.
  • CONCLUSION: Eighty-nine percent of our patients had a maximal rectal dose from ICRT at the proximal rectum instead of the ICRU rectal point.
  • It is important and useful to contrast the whole rectal wall up to the rectosigmoid junction and to calculate the dose at the proximal rectum for patients undergoing HDR ICRT.
  • [MeSH-major] Brachytherapy / adverse effects. Radiation Injuries / complications. Rectal Diseases / etiology. Rectum / radiation effects. Uterine Cervical Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14575832.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Simpkins F, Belinson JL, Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol; 2007 Oct;107(1):118-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
  • OBJECTIVES: Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor, has demonstrated activity in recurrent ovarian carcinoma.
  • A prior study from our institution demonstrated frequent (26%) transmural bowel wall involvement from ovarian cancer among patients who undergo intestinal resection at initial surgery.
  • Since the initial report of this complication, we have limited bevacizumab treatment to patients without:.
  • 1) clinical symptoms of bowel obstruction 2) evidence of rectosigmoid involvement on pelvic exam 3) bowel involvement on CT scan.
  • METHODS: Patients with advanced recurrent ovarian cancer treated with single agent or combination bevacizumab therapy (15 mg/kg every 21 days) were retrospectively identified.
  • All patients met the above criteria of no apparent bowel involvement.
  • Response to therapy was stratified by the presence or absence of bulky disease.
  • RESULTS: Twenty-five patients (21 primary ovarian cancers; 4 primary peritoneal) had received a median of 5 (range 2-12) prior chemotherapy regimens and 3 (range 1-6) prior platinum containing regimens.
  • All patients were platinum resistant prior to bevacizumab therapy.
  • Ten patients (40%; 95% CI: (27%, 63%)) received a median of 4 cycles (range 1-24) of bevacizumab as a single agent and 15 patients (60%; 95% CI: (41%, 77%)) received bevacizumab in combination with cytotoxic therapy.
  • The overall response rate (partial response) was 28% (7 patients; 95% CI: (14%, 48%)) with a 20% (2 of 10 patients; 95% CI: (5.7%, 51%)) and 33% (5 of 15 patients; 95% CI: (15%, 58%)) response rate with bevacizumab as single agent therapy and as combination therapy, respectively.
  • CONCLUSION: Bevacizumab demonstrates activity in recurrent platinum resistant ovarian cancer.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Intestines / drug effects. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Drug Resistance, Bacterial. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Platinum Compounds / therapeutic use. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658587.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Platinum Compounds; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


28. Soran A, Harlak A, Wilson JW, Nesbitt L, Lembersky BC, Wienad HS, O'Connell MJ: Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06. Clin Colorectal Cancer; 2006 Jul;6(2):140-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.
  • BACKGROUND: Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD).
  • National Surgical Adjuvant Breast and Bowel Project (NASBP) protocol C-06 is a clinical trial comparing oral uracil/tegafur/leucovorin with 5-fluorouracil/leucovorin in patients with resected stage II/III carcinoma of the colon.
  • PATIENTS AND METHODS: The NASBP enrolled 1,608 patients who had undergone potentially curative resection for stage II/III colon cancer from 256 medical sites between February 14, 1997, and March 31, 1999.
  • Colon cancer was located in the rectosigmoid in 46.88% of patients with DD and in 31.92% of patients without DD (P < 0.05).
  • [MeSH-major] Colonic Neoplasms / complications. Colonic Neoplasms / drug therapy. Diverticulum, Colon / etiology

  • Genetic Alliance. consumer health - Diverticular Disease.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945170.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10CA-69651; United States / NCI NIH HHS / CA / U10CA-69974
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement